Manupati Surya

Multi-target Therapy with Rituximab plus Mycophenolate Mofetil versus Rituximab Monotherapy in Systemic Sclerosis–Associated Interstitial Lung Disease

Objective To compare the effectiveness and safety of rituximab (RTX) plus mycophenolate mofetil (MMF) versus RTX monotherapy in patients with SSc-ILD. Methods We performed a retrospective comparative analysis among adults with radiologically confirmed SSc–ILD treated with rituxim...